We are studying whether ruxolitinib, combined with standard care, can improve organ function and survival in critically ill patients with acquired hemophagocytic syndrome. This trial also looks at the safety and effects of the drug on various health markers.
Health conditions and diseases that the clinical trial is designed to study and treat.
Haemophagocytic syndrome is a severe immune response where the body’s immune system becomes overly activated, leading to the destruction of blood cells and various symptoms. It can be triggered by infections, autoimmune diseases, or malignancies.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.